Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
- Released
- 2026-10-29 11:24
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.
Your picks build your own list. Add items to lists and rank them.
Theme
Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.